| NCT04498117 | III | Newly diagnosed stage III/IV ovarian cancer without BRCA1/2 mutations following optimal cytoreduction at primary or interval surgery | A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | AZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MI, MN, NE, NH, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WA, WI | View Drugs | View Results |
Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|